Neuphoria Therapeutics Inc Ordinary Shares NEUP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?
-
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—UTZ, NEUP, SAFT, and NRIM
-
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)
Trading Information
- Previous Close Price
- $3.51
- Day Range
- $3.45–3.59
- 52-Week Range
- $3.19–21.40
- Bid/Ask
- $3.43 / $3.68
- Shares Outstanding
- 5.41M
- Market Cap
- $18.78M
- Volume/Avg
- 12,582 / 164,040
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1
- Website
- https://www.neuphoriatx.com
Valuation
|
Metric
|
NEUP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.76 |
Price/Sales | 12.99 |
Price/Cash Flow | — |
Price/Earnings
NEUP
Financial Strength
|
Metric
|
NEUP
|
|---|---|
Quick Ratio | 27.33 |
Current Ratio | 27.85 |
Interest Coverage | — |
Quick Ratio
NEUP
Profitability
|
Metric
|
NEUP
|
|---|---|
Return on Assets (Normalized) | −30.44% |
Return on Equity (Normalized) | −41.23% |
Return on Invested Capital (Normalized) | −43.94% |
Return on Assets
NEUP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|cC^<&>n | LOCK|!vf% | $128B | |||
| Moderna Inc
MRNA
| LOCK|Jff<$> | LOCK|$K% | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$TZXWV | LOCK|#Djn | $76B | |||
| argenx SE ADR
ARGX
| LOCK|@?Qp$#< | LOCK|tZ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&@?NbR | LOCK|?# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$m#>PP | LOCK|#Xftk | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|JN@qkR? | LOCK|GV&% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|?T&f%z | LOCK|yC | $24B | |||
| Incyte Corp
INCY
| LOCK|m??W&p | LOCK|>y | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%wBJL! | LOCK|mb | $15B |
United States